Impulse Dynamics Secures $158M to Accelerate Heart Failure Pipeline

Impulse Dynamics has closed a $158 million financing round to support strategic growth, expand commercialization, and advance its clinical and technology pipelines for heart failure therapies.

The funding round was anchored by new institutional investors Sands Capital and Braidwell, with continued support from existing investors including Redmile, Perceptive, and Alger, as well as several prominent industry executives. The investment underscores growing confidence in Impulse Dynamics’ vision and its role in addressing unmet needs in heart failure care.

The financing follows a major regulatory milestone for the company: a recent Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) for Cardiac Contractility Modulation (CCM®) therapy. The decision expands access to CCM therapy for more than 66 million Medicare beneficiaries and formally establishes the therapy as no longer experimental or investigational. CCM therapy was also selected as one of only five technologies for inclusion in CMS’s Transitional Coverage for Emerging Technologies (TCET) pathway in 2025.

To date, more than 12,000 patients have received CCM therapy worldwide. The NCD removes a significant reimbursement barrier, paving the way for broader adoption among heart failure patients who continue to experience debilitating symptoms despite optimal medical therapy.

Impulse Dynamics plans to use the new capital to expand access to CCM therapy while accelerating development of next-generation technologies, including the investigational CCM-D® HF System. The single device is designed to deliver both CCM therapy for heart failure symptom relief and implantable cardioverter defibrillator (ICD) therapy, which provides life-saving protection against sudden cardiac death.

The company is also advancing several key clinical trials. These include the INTEGRA-D trial, which is evaluating the CCM-D HF System in patients who already require an ICD, and the AIM HIGHer trial, focused on patients with diastolic heart failure, an area with limited treatment options that represents approximately half of all heart failure cases.

With a strengthened balance sheet, expanding reimbursement coverage, and a growing clinical pipeline, Impulse Dynamics is positioning itself as a leader in device-based therapies aimed at improving quality of life for people living with heart failure.